Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New combination treatment for hepatitis C reported more beneficial than standard therapy

27.09.2002


he New England Journal of Medicine’s Sept. 26 issue carries the first published report showing that a combination treatment with peginterferon alfa-2a (Pegasys) - a new long-acting interferon drug - and an antiviral medication is more beneficial than the standard combination therapy for people with the most-difficult-to-treat and most common strain of hepatitis C.



The large international study, headed by researchers at the University of North Carolina at Chapel Hill, is also the first published one to show that treatment with the investigational drug peginterferon alfa-2a in combination with the oral antiviral medication, ribavirin, is linked to a lower rate of troublesome side effects - depression, flu-like symptoms (chills, headache and fever) - than the standard interferon (Rebetron) and ribavirin.

"Sixty-five percent of patients in the study were infected with hepatitis C genotype 1, the most prevalent genotype we see here in the United States, and typically the least responsive to therapy," said study co-author Dr. Michael W. Fried, associate professor of medicine and director of clinical hepatology at the UNC School of Medicine.


"With this research, we’ve found the most significant evidence to date suggesting these patients might benefit by taking peginterferon alfa-2a in combination with ribavirin."

According to Fried, side effects of therapy can be very challenging for patients. "The study shows an approach that can offer patients superior efficacy without increases in some of the most common and difficult to tolerate adverse events associated with hepatitis C therapy."

Of the six different strains, or genotypes, of hepatitis C, approximately 70 percent of people in North America are infected with genotype 1.

The study was funded by Hoffmann-La Roche, the maker of Pegasys, and was conducted at 81 clinical sites in 18 countries. More than 1,100 patients were involved in one of three study arms: 453 were treated with peginterferon alfa-2a plus oral ribavirin, 224 with peginterferon alfa-2a plus placebo and 444 with interferon alfa-2b plus ribavirin. Patients were treated for 48 weeks and then monitored for an additional 24 weeks.

A key variable measured by the study was sustained viral response, defined as undetectable serum hepatitis C RNA after the treatment-free follow-up period.

Overall, patients treated with the peginterferon alfa-2a plus ribavirin combination achieved a 56 percent sustained response rate as compared to patients taking Rebetron (44 percent). Patients with genotype 1 had a sustained response rate of 46 percent, compared to patients on Rebetron (36 percent) and those on Pegasys plus placebo (21 percent).

A retrospective analysis of the data showed that response to PEG interferon alpha-2a plus ribavirin is predictable. At week 12, 86 percent of patients treated with PEG interferon demonstrated an early viral response; of these, 65 percent attained a sustained viral response. However, 97 percent of patients who did not respond by week 12 failed to achieve a sustained response.

"This means that physicians can create an alternate treatment plan for patients who do not show any response by week 12," said Fried. "And for those who do respond, it can be a motivation to continue to adhere to their treatment regimens."

Dr. Fried added that these treatment decisions must be individualized for each patient.

The hepatitis C virus is a life-threatening viral infection of the liver transmitted primarily through infected blood and blood products. Approximately 2.7 million Americans and 170 million people worldwide are chronically infected with the virus, which is often described as "silent" because people may be infected for 10 to 30 years and not exhibit symptoms, yet still be carrying the virus.

While many patients with the hepatitis C virus will not develop complications from their liver disease, chronic hepatitis C is still a leading cause of cirrhosis and liver cancer and is the major indication for liver transplants in this country.

The UNC Center for Liver Diseases and Transplantation provides highly specialized care for liver diseases for residents of North Carolina and surrounding regions. In addition to its commitment to patient care, the UNC liver program is dedicated to studying novel therapies for viral hepatitis, other chronic liver diseases and transplantation.


Contact note: Fried is available at (919) 966-8784 or mfried@med.unc.edu

Leslie Lang | EurekAlert!
Further information:
http://www.med.unc.edu/

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>